KIF5B-RET is the most common RET fusion in NSCLC (~70% of RET+ NSCLC). Treatment is ident...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RET-KIF5B-NSCLC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-NSCLC |
| Sources | SRC-CIVIC SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Actionability Facts
| Biomarker | BIO-RET |
|---|---|
| Variant | KIF5B-RET fusion |
| Disease | DIS-NSCLC |
| ESCAT tier | IA |
| Recommended combinations | selpercatinib monotherapy, pralsetinib monotherapy |
| Contraindicated monotherapy | cabozantinib / vandetanib (inferior in selective-TKI era) |
| Evidence summary | KIF5B-RET is the most common RET fusion in NSCLC (~70% of RET+ NSCLC). Treatment is identical to gene-level RET fusion: selpercatinib (LIBRETTO-001 / LIBRETTO-431) and pralsetinib (ARROW). Deep CNS penetrance with selpercatinib (intracranial ORR 82%). |
Notes
ESCAT IA. OncoKB Level 1. Fusion-partner-specific cell maintained for completeness (matches BMA-ALK-EML4-V1-NSCLC pattern).
Used By
No reverse references found in the YAML corpus.